What is Barclays's price target for ABBV?

Barclays's latest stated price target for AbbVie Inc. (ABBV) is $275, from its action on Feb 20, 2026.

What is Barclays's rating on ABBV?

Barclays rates ABBV Overweight, a bullish rating, as of Feb 20, 2026.

When did Barclays last change its view on ABBV?

On Feb 20, 2026, Barclays starts coverage at Overweight, price target $275.

Barclays ABBV price target and rating history

Barclays rates AbbVie Inc. (ABBV) Overweight with a $275 price target, as of its latest action on Feb 20, 2026. It has published 5 rating actions on ABBV since November 2021, including 1 upgrade and 0 downgrades. Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. Barclays's $275 is 4% above that.

Current rating: Overweight
Price target: $275
Median target, all firms: $263.50
Actions on ABBV: 5

Barclays price target on ABBV

Barclays price target on ABBV, each point a stated target, November 2021 to February 2026.

Every Barclays rating on ABBV

Feb 20, 2026
InitiateBarclays starts coverage at Overweight, price target $275
Oct 30, 2023
UpgradeBarclays upgrades to Overweight from Equal Weight, price target $160 to $170
Feb 3, 2022
ReiterateBarclays raises its price target to $150 from $133, keeps Equal-Weight
Jan 20, 2022
ReiterateBarclays raises its price target to $133 from $118, keeps Equal-Weight
Nov 1, 2021
ReiterateBarclays raises its price target to $118 from $112, keeps Equal-Weight

How other firms rate ABBV

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Wolfe Research	Outperform	$300	Aug 13, 2026
Erste Group	Buy		Aug 5, 2026
BofA Securities	Buy	$234	Apr 30, 2026
Canaccord Genuity	Buy	$262	Apr 21, 2026
RBC Capital Markets	Outperform	$260	Feb 25, 2026
Barclays	Overweight	$275	Feb 20, 2026
UBS	Neutral	$240	Jan 7, 2026
HSBC	Buy	$265	Dec 10, 2025
Scotiabank	Sector Outperform	$280	Nov 13, 2025

Questions about Barclays and ABBV

What is Barclays's price target for ABBV?: Barclays's latest stated price target for AbbVie Inc. (ABBV) is $275, from its action on Feb 20, 2026.
What is Barclays's rating on ABBV?: Barclays rates ABBV Overweight, a bullish rating, as of Feb 20, 2026.
When did Barclays last change its view on ABBV?: On Feb 20, 2026, Barclays starts coverage at Overweight, price target $275.
How does Barclays's ABBV target compare with other analysts?: Across 8 firms with a ABBV price target in the last 12 months, the median target is $263.50. Barclays's $275 is 4% above that.

More ABBV rating histories

All Barclays ratings ABBV news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.